INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 10,023 | $467.53 | 591,569 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 8,542 | $468.49 | 583,027 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 7,250 | $469.46 | 575,777 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 5,531 | $470.48 | 570,246 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 5,258 | $471.34 | 564,988 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 10,270 | $472.56 | 554,718 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 8,024 | $473.39 | 546,694 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 7,060 | $474.52 | 539,634 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 4,223 | $475.43 | 535,411 |
| Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 50,545 | $476.42 | 563,990 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.